載入...
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions
Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent presence of mult...
Na minha lista:
| 發表在: | Drugs |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer International Publishing
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4532715/ https://ncbi.nlm.nih.gov/pubmed/26187774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-015-0440-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|